Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy) acetamide-based antituberculosis agents

被引:40
作者
Borsoi, Ana Flavia [1 ,2 ]
Paz, Josiane Delgado [1 ,3 ]
Abbadi, Bruno Lopes [1 ]
Macchi, Fernanda Souza [1 ,3 ]
Sperotto, Nathalia [1 ,2 ]
Pissinate, Kenia [1 ]
Rambo, Raoni S. [1 ]
Ramos, Alessandro Silva [1 ]
Machado, Diana [4 ]
Viveiros, Miguel [4 ]
Bizarro, Cristiano Valim [1 ,3 ]
Basso, Luiz Augusto [1 ,2 ,3 ]
Machado, Pablo [1 ,3 ]
机构
[1] Pontificia Univ Catolica Rio Grande do Sul, Ctr Pesquisas Biol Mol & Func, Inst Nacl Ciencia & Tecnol Tuberculose, BR-90616900 Porto Alegre, RS, Brazil
[2] Pontificia Univ Catolica Rio Grande do Sul, Programa Posgrad Med & Ciencias Saude, BR-90616900 Porto Alegre, RS, Brazil
[3] Pontificia Univ Catolica Rio Grande do Sul, Programa Posgrad Biol Celular & Mol, BR-90616900 Porto Alegre, RS, Brazil
[4] Univ NOVA Lisboa, Inst Higiene & Med Trop, UNL, IHMT,GHTM, Lisbon, Portugal
关键词
Mycobacterium tuberculosis; Molecular simplification; Multidrug-resistant strains; SAR; Intracellular activity; Cytochrome bc(1) complex; DRUG DISCOVERY; 2-(QUINOLIN-4-YLOXY)ACETAMIDES; RESISTANCE; CHALLENGE; DELAMANID; LEADS; ASSAY;
D O I
10.1016/j.ejmech.2020.112179
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Using a classical molecular simplification approach, a series of 36 quinolines were synthesized and evaluated as in vitro inhibitors of Mycobacterium tuberculosis (M. tuberculosis) growth. Structure-activity relationship (SAR) studies leaded to potent antitubercular agents, with minimum inhibitory concentration ( MIC) values as low as 0.3 mu M against M. tuberculosis H37Rv reference strain. Furthermore, the lead compounds were active against multidrug-resistant strains, without cross-resistance with some first- and second-line drugs. Testing the molecules against a spontaneous mutant strain containing a single mutation in the qcrB gene (T313A) indicated that the synthesized quinolines targeted the cytochrome bc(1) complex. In addition, leading compounds were devoid of apparent toxicity to HepG2 and Vero cells and showed moderate elimination rates in human liver S9 fractions. Finally, the selected structures inhibited M. tuberculosis growth in a macrophage model of tuberculosis infection. Taken together, these data indicate that this class of compounds may furnish candidates for the future development of antituberculosis drugs. (c) 2020 Published by Elsevier Masson SAS.
引用
收藏
页数:10
相关论文
共 19 条
[1]  
[Anonymous], 2017, Global tuberculosis report
[2]   Fueling Open-Source Drug Discovery: 177 Small-Molecule Leads against Tuberculosis [J].
Ballell, Lluis ;
Bates, Robert H. ;
Young, Rob J. ;
Alvarez-Gomez, Daniel ;
Alvarez-Ruiz, Emilio ;
Barroso, Vanessa ;
Blanco, Delia ;
Crespo, Benigno ;
Escribano, Jaime ;
Gonzalez, Ruben ;
Lozano, Sonia ;
Huss, Sophie ;
Santos-Villarejo, Angel ;
Julio Martin-Plaza, Jose ;
Mendoza, Alfonso ;
Jose Rebollo-Lopez, Maria ;
Remuinan-Blanco, Modesto ;
Luis Lavandera, Jose ;
Perez-Herran, Esther ;
Javier Gamo-Benito, Francisco ;
Francisco Garcia-Bustos, Jose ;
Barros, David ;
Castro, Julia P. ;
Cammack, Nicholas .
CHEMMEDCHEM, 2013, 8 (02) :313-321
[3]   Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis [J].
Bloemberg, Guido V. ;
Gagneux, Sebastien ;
Boettger, Erik C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (20) :1986-1988
[4]   The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis [J].
Diacon, Andreas H. ;
Pym, Alexander ;
Grobusch, Martin ;
Patientia, Ramonde ;
Rustomjee, Roxana ;
Page-Shipp, Liesl ;
Pistorius, Christoffel ;
Krause, Rene ;
Bogoshi, Mampedi ;
Churchyard, Gavin ;
Venter, Amour ;
Allen, Jenny ;
Palomino, Juan Carlos ;
De Marez, Tine ;
van Heeswijk, Rolf P. G. ;
Lounis, Nacer ;
Meyvisch, Paul ;
Verbeeck, Johan ;
Parys, Wim ;
de Beule, Karel ;
Andries, Koen ;
Mc Neeley, David F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (23) :2397-2405
[5]   4-Substituted Thioquinolines and Thiazoloquinolines: Potent, Selective, and Tween-80 in vitro Dependent Families of Antitubercular Agents with Moderate in vivo Activity [J].
Escribano, Jaime ;
Rivero-Hernandez, Cristina ;
Rivera, Hilda ;
Barros, David ;
Castro-Pichel, Julia ;
Perez-Herran, Esther ;
Mendoza-Losana, Alfonso ;
Angulo-Barturen, Inigo ;
Ferrer-Bazaga, Santiago ;
Jimenez-Navarro, Elena ;
Ballell, Lluis .
CHEMMEDCHEM, 2011, 6 (12) :2252-2263
[6]   New insights into the SAR and drug combination synergy of 2(quinolin-4-yloxy)acetamides against Mycobacterium tuberculosis [J].
Giacobbo, Bruno Couto ;
Pissinate, Kenia ;
Rodrigues-Junior, Valnes ;
Villela, Anne Drumond ;
Grams, Estevao Silveira ;
Abbadi, Bruno Lopes ;
Subtil, Fernanda Teixeira ;
Sperotto, Nathalia ;
Trindade, Rogerio Valim ;
Back, Davi Fernando ;
Campos, Maria Martha ;
Basso, Luiz Augusto ;
Machado, Pablo ;
Santos, Diogenes Santiago .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 126 :491-501
[7]  
Gler MT, 2012, NEW ENGL J MED, V366, P2151, DOI 10.1056/NEJMoa1112433
[8]  
Kerns E.H., 2008, DRUG PROPRIETIES CON
[9]   The challenge of new drug discovery for tuberculosis [J].
Koul, Anil ;
Arnoult, Eric ;
Lounis, Nacer ;
Guillemont, Jerome ;
Andries, Koen .
NATURE, 2011, 469 (7331) :483-490
[10]   1H-Benzo[d]imidazoles and 3,4-dihydroquinazolin-4-ones: Design, synthesis and antitubercular activity [J].
Macchi, Fernanda Souza ;
Pissinate, Kenia ;
Villela, Anne Drumond ;
Abbadi, Bruno Lopes ;
Rodrigues-Junior, Valnes ;
Nabinger, Debora Dreher ;
Altenhofen, Stefani ;
Sperotto, Nathalia ;
Dadda, Adilio da Silva ;
Subtil, Fernanda Teixeira ;
de Freitas, Talita Freitas ;
Erhart Rauber, Ana Paula ;
Borsoi, Ana Flavia ;
Bonan, Carla Denise ;
Bizarro, Cristiano Valim ;
Basso, Luiz Augusto ;
Santos, Diogenes Santiago ;
Machado, Pablo .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 155 :153-164